18.91
+0.24(+1.29%)
Currency In USD
| Previous Close | 18.67 |
| Open | 18.57 |
| Day High | 19.11 |
| Day Low | 18.21 |
| 52-Week High | 20.72 |
| 52-Week Low | 3.39 |
| Volume | 140,671 |
| Average Volume | 416,680 |
| Market Cap | 213.57M |
| PE | -1.41 |
| EPS | -13.42 |
| Moving Average 50 Days | 17.29 |
| Moving Average 200 Days | 9.74 |
| Change | 0.24 |
If you invested $1000 in Avalo Therapeutics, Inc. (AVTX) 10 years ago, it would be worth $1.65 as of December 24, 2025 at a share price of $18.91. Whereas If you bought $1000 worth of Avalo Therapeutics, Inc. (AVTX) shares 5 years ago, it would be worth $2.39 as of December 24, 2025 at a share price of $18.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 17, 2025 9:30 PM GMT
WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the C
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expans